ArticleACS nano2017
Analgesic Microneedle Patch for Neuropathic Pain Therapy.
Article in ACS nano, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 162 citations in OpenAlex.
- Microdermabrasion with Calcium Hydrogen Phosphate for Enhancing Skin Permeation of Lidocaine-tetracaine Eutectic Microemulsion Gel.Pharmaceutical research · 2026Article
- The application prospect of microneedles for sports injuries: a narrative review.Annals of medicine · 2025Review
- Dexmedetomidine-Loaded Hydrogel Microneedles Alleviate Acute Inflammatory Visceral Pain in Mice.Gels (Basel, Switzerland) · 2025Article
- Ropivacaine-loaded tumor-derived vesicles targeting CCNB1 and autophagy in nasopharyngeal carcinoma.Materials today. Bio · 2025Article
- Single Polysaccharide Dissolvable Microneedles for Painless Local Anesthesia: Fabrication, Characterization, andACS biomaterials science & engineering · 2025Article
- Emerging treatments for chronic neuropathic pain from a cross-disease perspective: developments and applications of nanomaterials.The journal of headache and pain · 2025Review
- Progressive microneedles for targeting and intelligent drug delivery.Asian journal of pharmaceutical sciences · 2025Review
- Advances in microneedle-based drug delivery system for metabolic diseases: structural considerations, design strategies, and future perspectives.Journal of nanobiotechnology · 2025Review
- The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals.Pharmaceutics · 2025Review
- Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies.Pharmaceutics · 2025Review
- Deciphering Pain and Pruritus in Keloids from the Perspective of Neurological Dysfunction: Where Are We Now?Biomedicines · 2025Article
- Double-Layer Microneedle Patch Loaded with HA-PBA-QCT for Management of Paclitaxel-Induced Peripheral Neuropathic Pain.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Current Status of Microneedle Array Technology for Therapeutic Delivery: From Bench to Clinic.Molecular biotechnology · 2024Review
- Mannose-coated nanozyme for relief from chemotherapy-induced peripheral neuropathic pain.iScience · 2023Article
- Strategies for Improving Transdermal Administration: New Approaches to Controlled Drug Release.Pharmaceutics · 2023Review
- A Pharmacological Review of Calcitonin Gene-Related Peptide Biologics and Future Use for Chronic Pain.Cureus · 2023Review
- Modeling of Microneedle Arrays in Transdermal Drug Delivery Applications.Pharmaceutics · 2023Article
- Biodegradable double-network GelMA-ACNM hydrogel microneedles for transdermal drug delivery.Frontiers in bioengineering and biotechnology · 2023Article
- Potential novel therapeutic strategies for neuropathic pain.Frontiers in molecular neuroscience · 2023Review
- Industrial perspectives for personalized microneedles.Beilstein journal of nanotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
Neuropathic pain caused by nerve injury is debilitating and difficult to treat. Current systemic pharmacological therapeutics for neuropathic pain produce limited pain relief and have undesirable side effects, while current local anesthetics tend to nonspecifically block both sensory and motor functions. Calcitonin gene related peptide (CGRP), a neuropeptide released from sensory nerve endings, appears to play a significant role in chronic neuropathic pain. In this study, an analgesic microneedle (AMN) patch was developed using dissolvable microneedles to transdermally deliver selective CGRP antagonist peptide in a painless manner for the treatment of localized neuropathic pain. Local analgesic effects were evaluated in rats by testing behavioral pain sensitivity in response to thermal and mechanical stimuli using neuropathic pain models such as spared-nerve injury and diabetic neuropathy pain, as well as neurogenic inflammatory pain model induced by ultraviolet B (UVB) radiation. Unlike several conventional therapies, the AMN patches produced effective analgesia on neuropathic pain without disturbing the normal nociception and motor function of the rat, resulting from the high specificity of the delivered peptide against CGRP receptors. The AMN patches did not cause skin irritation or systemic side effects. These results demonstrate that dissolvable microneedle patches delivering CGRP antagonist peptide provide an effective, safe, and simple approach to mitigate neuropathic pain with significant advantages over current treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.